CervoMed Inc.
CRVO · XNASCIK 1053691fmd_1B60W7SB3YB8FHGRYCE12A5QC7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 0 | 7 | 10 | 4 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 7 | 5 | 6 | 7 | 9 | 8 | 1 | 8 | 19 | 22 |
| Total operating expenses | – | – | – | – | – | – | 3 | 15 | 28 | 32 |
| Operating income | (18) | (11) | (19) | (12) | (16) | (25) | (3) | (8) | (18) | (28) |
| Interest expense | 0 | 0 | 0 | – | – | – | 0 | 0 | – | – |
| Interest and investment income | – | – | – | – | – | – | 0 | 0 | 2 | 1 |
| Other non-operating income (expense) | – | – | – | – | – | – | (2) | 6 | 2 | 1 |
| Income before taxes | (18) | (2) | (19) | (11) | (16) | (25) | (16) | – | – | – |
| Income tax expense | (0) | (1) | (0) | 0 | (2) | (0) | 0 | – | – | 0 |
| Net income from continuing operations | (18) | (1) | (18) | (12) | (14) | (24) | (16) | – | – | – |
| Net income | (18) | (1) | (18) | (12) | (14) | (24) | (6) | (2) | (16) | (27) |
| Net income to common shareholders | (18) | (3) | (27) | (12) | (16) | (24) | – | – | – | – |